search
Back to results

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) (BRAVIO)

Primary Purpose

Snakebite, Envenoming, Snake

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Varespladib intravenous form
varespladib-methyl- oral form
Placebo intravenous form
Placebo - oral form
Sponsored by
Ophirex, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Snakebite focused on measuring Envenoming, Snakebite, varespladib, antidote, snake

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

INCLUSION CRITERIA: Is a male or female ≥ 18 years of age with venomous snakebite. Patients must have known or suspected venomous snakebite. In India, enrollment will be restricted to patients bitten by suspected or confirmed Russell's viper (Daboia russelii) or krait (Bungarus spp.) In the U.S., any snakebite that meets all other criteria may be eligible. Participants must meet one of two categories of inclusion criteria: Category 1: The participant is enrolled within 5 hours of venomous snakebite or symptom onset with an SSS score of ≥2 in one system and ≥1 in another system (2+1). OR Category 2: The participant has a suspected or confirmed bite from an elapid and is enrolled within 10 hours of bite or symptom onset with moderate to severe cranial nerve or skeletal muscle weakness. Is willing (or legally authorized representative is willing) to provide informed consent prior to initiation of any study procedures. EXCLUSION CRITERIA: Has history of or is suspected to have CVA or intracranial bleeding of any kind, acute coronary syndrome, MI, or severe pulmonary hypertension. Has known history of inherited bleeding or coagulation disorder. Is, at Screening Visit, using the following anticoagulants: warfarin/coumadin, argatroban, bilvalirudin, lepirudin, apixaban, dabigatran, clopidogrel, prasugrel, ticlodipine or another anticoagulant agent not specifically listed, or has used heparin, enoxaparin, fondaparinux, or other low molecular weight heparin or any antiarrhythmic drugs within 14 days prior to treatment. Has a history of chronic liver disease such as chronic active viral hepatitis, alcohol- related liver disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis. Reports or has known pre-existing renal impairment or chronic kidney disease. Has a known allergy or significant adverse reaction to varespladib or varespladib-methyl. Is considered by the Investigator to be unable to comply with protocol requirements due to geographic considerations, psychiatric disorders, or other compliance concerns. Is pregnant, has a positive serum human chorionic gonadotropin (hCG) pregnancy test or not willing to use a highly effective method of contraception for 14 days after initial treatment, or is breast-feeding.

Sites / Locations

  • Banner University Medical Center - Phoenix
  • Arizona Poison & Drug Information CenterRecruiting
  • Loma Linda University Medical Center
  • Desert Regional Medical CenterRecruiting
  • Antelope Valley Medical CenterRecruiting
  • University of South Florida/Tampa General Hospital
  • Emergency Medicine, University of KentuckyRecruiting
  • Duke University Medical CenterRecruiting
  • Texas Tech University Health Sciences Center El Paso
  • UT Health San Antonio

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Varespladib Intravenous Form (IV) + Varespladib Oral tablet (LY315920) + SOC

Placebo Intravenous (IV) + Placebo Oral + SOC

Arm Description

Participants will receive intravenous (IV) infusion of varespladib at dose of 0.45 milligrams per kilogram per hour (mg/kg/hr) for six hours. This infusion will continue until when the participant meets clinical criteria for transition to oral drug, -If criteria are met, they will be transitioned to varespladib-methyl (initial dose of 500 mg) then continued oral dosing q12 (once every 12 hours) of 250 mg for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion at 0.45 mg/kg/hr (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.

Participants will receive intravenous (IV) infusion of placebo matched to varespladib for six hours. This infusion will continue until the participant meets clinical criteria for transition to oral drug. If criteria are met, they will be transitioned to the oral placebo then continued oral dosing for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.

Outcomes

Primary Outcome Measures

Area under the curve of the composite outcome of the pulmonary, cardiovascular, local wound, hematologic, renal and nervous system sections of the snakebite severity score (SSS) from Baseline (pre-dosing) to Day 7.
The Snakebite Severity Scale is a tool used to measure the severity of envenoming based on 7 body categories: local wound, pulmonary, cardiovascular, gastrointestinal (graded at levels from Grade 0 to Grade 3), hematological, renal and nervous system effects (graded at levels from Grade 0 to Grade 4). A higher score indicates worse symptoms. For the primary outcome, 5 body categories (local wound, pulmonary, cardiovascular, hematological, and nervous system) will be included.

Secondary Outcome Measures

Area under the curve of the composite outcome of pulmonary, cardiovascular, local wound, hematologic, renal, and nervous system sections of the SSS from Baseline to Day 7, among patients receiving study drug, 6 hours after bite or symptom onset
The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms.
Change in the composite outcome of pulmonary, cardiovascular, hematologic, renal, and nervous system sections of the SSS from Baseline to the average of the scores 3 and 6 hours after the first dose.
The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms.
Pulmonary, cardiovascular, local wound, hematologic, renal, and nervous system sections of the composite Snakebite Severity Scale from Baseline through Day 7.
The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms.
Elapsed time from initiation
IV varespladib treatment until the transition to oral varespladib-methyl.
Complete Snakebite Severity Scale Scores from baseline to Day 7.
The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms.
Coagulation Abnormalities (subject coagulation lab tests: PT, PTT, fibrinogen, INR will be evaluated) from Baseline through Day 7
Each lab value that is outside of the normal reference range will be evaluated by the investigator to determine clinical relevance.
Hemolysis markers (subject hemolysis lab tests: free hemoglobin, haptoglobin, LDH will be evaluated) from Baseline through Day 3
Each lab value that is outside of the normal reference range will be evaluated by the investigator to determine clinical relevance.
Levels of the Myonecrosis Marker, Creatine Kinase (CK) from Baseline through Day 3
Kidney function markers (subject lab tests: creatinine, BUN, eGFR will be evaluated) from Baseline through Day 28
Each lab value that is outside of the normal reference range will be evaluated by the investigator to determine clinical relevance.
Numeric Pain Rating Scale (NPRS) score in patients able to respond pre-dosing through Day 28
The NPRS is an 11-point scale for participants self-reporting of pain with scores ranging from 0 (no pain) to 10 (worst possible pain).
Total Antivenom Requirement, measured in number of vials of antivenom administered to the subject, from baseline (pre-dosing) through Day 28
Head Lift duration (measured time of 0 - 5 seconds of subject's ability to lift head off of the bed, to determine neurological weakness) from Baseline through Day 7
Head lift is used to assess subject for neurological weakness.
Time from initiation of ventilatory support to initiation of weaning
Time of ventilatory support from Baseline through Day 28
Time of Intensive Care Unit (ICU) Stay from Baseline through Day 28
Time of Hospitalization from baseline (pre-dosing) through Day 28
All-cause mortality at Day 28
Clinical Global Impression - Improvement (CGI-I) from Baseline through Day 28
Clinical Global Impression - Improvement Scale is 0, not assessed, 1 = very much improved to 7 = very much worse
Patient-Specific Functional Scale (PSFS) total score from Baseline through Day 28
A 3 item instrument administered verbally; 0= unable to perform activity to 10 = able to perform activity at same level as before injury or problem
Patient Global Impression of Change (PGIC) from Baseline through Day 28
Scale is 1 = no change, to 7= a great deal better

Full Information

First Posted
January 20, 2023
Last Updated
September 27, 2023
Sponsor
Ophirex, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05717062
Brief Title
Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)
Acronym
BRAVIO
Official Title
Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Varespladib Followed by Oral Varespladib in Addition to Standard of Care in Subjects Bitten by Venomous Snakes
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 30, 2023 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
November 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ophirex, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multicenter,randomized,double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability and efficacy of a continuous rate infusion (CRI) of IV varespladib followed by transition to the oral dosage form, varespladib-methyl, concurrently with SOC, in participants bitten by venomous snakes. Note: Funding Source - FDA-OOPD
Detailed Description
This is a multicenter, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability and efficacy of intravenous varespladib followed by oral varespladib, concurrently with standard of care (SOC), in participants bitten by venomous snakes. Approximately 140 male and female eligible participants will be enrolled and randomized to receive active varespladib or placebo (in addition to SOC) Randomization will be stratified by the presence or absence of neurotoxicity (SSS nervous system subscore of 0-1 or ≥ 2) at Baseline, and by receipt of antivenom prior to screening, resulting in 4 strata in total.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Snakebite, Envenoming, Snake
Keywords
Envenoming, Snakebite, varespladib, antidote, snake

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Varespladib Intravenous Form (IV) + Varespladib Oral tablet (LY315920) + SOC
Arm Type
Experimental
Arm Description
Participants will receive intravenous (IV) infusion of varespladib at dose of 0.45 milligrams per kilogram per hour (mg/kg/hr) for six hours. This infusion will continue until when the participant meets clinical criteria for transition to oral drug, -If criteria are met, they will be transitioned to varespladib-methyl (initial dose of 500 mg) then continued oral dosing q12 (once every 12 hours) of 250 mg for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion at 0.45 mg/kg/hr (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.
Arm Title
Placebo Intravenous (IV) + Placebo Oral + SOC
Arm Type
Active Comparator
Arm Description
Participants will receive intravenous (IV) infusion of placebo matched to varespladib for six hours. This infusion will continue until the participant meets clinical criteria for transition to oral drug. If criteria are met, they will be transitioned to the oral placebo then continued oral dosing for the remainder of the study period. Participants that do not meet the criteria for transitioning to the oral drug will remain on the IV infusion (along with SOC) and assessed twice a day until they meet criteria for transition to oral drug.
Intervention Type
Drug
Intervention Name(s)
Varespladib intravenous form
Other Intervention Name(s)
LY315920
Intervention Description
This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
Intervention Type
Drug
Intervention Name(s)
varespladib-methyl- oral form
Other Intervention Name(s)
LY333013
Intervention Description
Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
Intervention Type
Drug
Intervention Name(s)
Placebo intravenous form
Intervention Description
The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
Intervention Type
Drug
Intervention Name(s)
Placebo - oral form
Intervention Description
Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
Primary Outcome Measure Information:
Title
Area under the curve of the composite outcome of the pulmonary, cardiovascular, local wound, hematologic, renal and nervous system sections of the snakebite severity score (SSS) from Baseline (pre-dosing) to Day 7.
Description
The Snakebite Severity Scale is a tool used to measure the severity of envenoming based on 7 body categories: local wound, pulmonary, cardiovascular, gastrointestinal (graded at levels from Grade 0 to Grade 3), hematological, renal and nervous system effects (graded at levels from Grade 0 to Grade 4). A higher score indicates worse symptoms. For the primary outcome, 5 body categories (local wound, pulmonary, cardiovascular, hematological, and nervous system) will be included.
Time Frame
Baseline to Day 7
Secondary Outcome Measure Information:
Title
Area under the curve of the composite outcome of pulmonary, cardiovascular, local wound, hematologic, renal, and nervous system sections of the SSS from Baseline to Day 7, among patients receiving study drug, 6 hours after bite or symptom onset
Description
The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms.
Time Frame
Baseline to Day 7
Title
Change in the composite outcome of pulmonary, cardiovascular, hematologic, renal, and nervous system sections of the SSS from Baseline to the average of the scores 3 and 6 hours after the first dose.
Description
The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms.
Time Frame
Baseline to 3 and 6 hours
Title
Pulmonary, cardiovascular, local wound, hematologic, renal, and nervous system sections of the composite Snakebite Severity Scale from Baseline through Day 7.
Description
The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms.
Time Frame
Baseline through Day 7
Title
Elapsed time from initiation
Description
IV varespladib treatment until the transition to oral varespladib-methyl.
Time Frame
Baseline to Day 28
Title
Complete Snakebite Severity Scale Scores from baseline to Day 7.
Description
The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms.
Time Frame
Baseline through Day 7
Title
Coagulation Abnormalities (subject coagulation lab tests: PT, PTT, fibrinogen, INR will be evaluated) from Baseline through Day 7
Description
Each lab value that is outside of the normal reference range will be evaluated by the investigator to determine clinical relevance.
Time Frame
Baseline through Day 7
Title
Hemolysis markers (subject hemolysis lab tests: free hemoglobin, haptoglobin, LDH will be evaluated) from Baseline through Day 3
Description
Each lab value that is outside of the normal reference range will be evaluated by the investigator to determine clinical relevance.
Time Frame
Baseline through Day 3
Title
Levels of the Myonecrosis Marker, Creatine Kinase (CK) from Baseline through Day 3
Time Frame
Baseline through Day 3
Title
Kidney function markers (subject lab tests: creatinine, BUN, eGFR will be evaluated) from Baseline through Day 28
Description
Each lab value that is outside of the normal reference range will be evaluated by the investigator to determine clinical relevance.
Time Frame
Baseline through Day 28
Title
Numeric Pain Rating Scale (NPRS) score in patients able to respond pre-dosing through Day 28
Description
The NPRS is an 11-point scale for participants self-reporting of pain with scores ranging from 0 (no pain) to 10 (worst possible pain).
Time Frame
Baseline through Day 28
Title
Total Antivenom Requirement, measured in number of vials of antivenom administered to the subject, from baseline (pre-dosing) through Day 28
Time Frame
Baseline through Day 28
Title
Head Lift duration (measured time of 0 - 5 seconds of subject's ability to lift head off of the bed, to determine neurological weakness) from Baseline through Day 7
Description
Head lift is used to assess subject for neurological weakness.
Time Frame
Baseline through Day 7
Title
Time from initiation of ventilatory support to initiation of weaning
Time Frame
Baseline through Day 28
Title
Time of ventilatory support from Baseline through Day 28
Time Frame
Baseline through Day 28
Title
Time of Intensive Care Unit (ICU) Stay from Baseline through Day 28
Time Frame
Baseline through Day 28
Title
Time of Hospitalization from baseline (pre-dosing) through Day 28
Time Frame
Baseline through Day 28
Title
All-cause mortality at Day 28
Time Frame
Baseline through Day 28
Title
Clinical Global Impression - Improvement (CGI-I) from Baseline through Day 28
Description
Clinical Global Impression - Improvement Scale is 0, not assessed, 1 = very much improved to 7 = very much worse
Time Frame
Baseline through Day 28
Title
Patient-Specific Functional Scale (PSFS) total score from Baseline through Day 28
Description
A 3 item instrument administered verbally; 0= unable to perform activity to 10 = able to perform activity at same level as before injury or problem
Time Frame
Baseline through Day 28
Title
Patient Global Impression of Change (PGIC) from Baseline through Day 28
Description
Scale is 1 = no change, to 7= a great deal better
Time Frame
Baseline through Day 28

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: Is a male or female ≥ 18 years of age with venomous snakebite. Patients must have known or suspected venomous snakebite. In India, enrollment will be restricted to patients bitten by suspected or confirmed Russell's viper (Daboia russelii) or krait (Bungarus spp.) In the U.S., any snakebite that meets all other criteria may be eligible. Participants must meet one of two categories of inclusion criteria: Category 1: The participant is enrolled within 5 hours of venomous snakebite or symptom onset with an SSS score of ≥2 in one system and ≥1 in another system (2+1). OR Category 2: The participant has a suspected or confirmed bite from an elapid and is enrolled within 10 hours of bite or symptom onset with moderate to severe cranial nerve or skeletal muscle weakness. Is willing (or legally authorized representative is willing) to provide informed consent prior to initiation of any study procedures. EXCLUSION CRITERIA: Has history of or is suspected to have CVA or intracranial bleeding of any kind, acute coronary syndrome, MI, or severe pulmonary hypertension. Has known history of inherited bleeding or coagulation disorder. Is, at Screening Visit, using the following anticoagulants: warfarin/coumadin, argatroban, bilvalirudin, lepirudin, apixaban, dabigatran, clopidogrel, prasugrel, ticlodipine or another anticoagulant agent not specifically listed, or has used heparin, enoxaparin, fondaparinux, or other low molecular weight heparin or any antiarrhythmic drugs within 14 days prior to treatment. Has a history of chronic liver disease such as chronic active viral hepatitis, alcohol- related liver disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis. Reports or has known pre-existing renal impairment or chronic kidney disease. Has a known allergy or significant adverse reaction to varespladib or varespladib-methyl. Is considered by the Investigator to be unable to comply with protocol requirements due to geographic considerations, psychiatric disorders, or other compliance concerns. Is pregnant, has a positive serum human chorionic gonadotropin (hCG) pregnancy test or not willing to use a highly effective method of contraception for 14 days after initial treatment, or is breast-feeding.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Brandi Ritter PA-C, MPAS
Phone
5302184454
Email
brandi@ophirex.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy Platts-Mills, MD, MSc
Organizational Affiliation
Ophirex, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Banner University Medical Center - Phoenix
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Arizona Poison & Drug Information Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85721
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elizabeth Campbell
Phone
520-626-8388
Email
bsalvag@email.arizona.edu
First Name & Middle Initial & Last Name & Degree
Farshad Shirazi, MD
Facility Name
Loma Linda University Medical Center
City
Loma Linda
State/Province
California
ZIP/Postal Code
92354
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tammy Phan, BS
Email
thphan@llu.edu
First Name & Middle Initial & Last Name & Degree
Brian Wolk, MD
Facility Name
Desert Regional Medical Center
City
Palm Springs
State/Province
California
ZIP/Postal Code
92262
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emily Coloma
Phone
760-416-4737
Email
emily.coloma@tenethealth.com
First Name & Middle Initial & Last Name & Degree
Suneil Agrawal, MD
Facility Name
Antelope Valley Medical Center
City
Rosamond
State/Province
California
ZIP/Postal Code
93560
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eileen Shu, MD
Email
eileen.shu@ucsf.edu
First Name & Middle Initial & Last Name & Degree
Eileen Shu, MD
Facility Name
University of South Florida/Tampa General Hospital
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ashley Bader
Email
abader@tgh.org
First Name & Middle Initial & Last Name & Degree
Justin Arnold, DO
Facility Name
Emergency Medicine, University of Kentucky
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ronda Petrey
Phone
859-323-5212
Email
ronda.petrey@uky.edu
First Name & Middle Initial & Last Name & Degree
Peter Akpunonu, MD
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dana Giangiacomo
Phone
919-684-3821
Email
dana.giangiacomo@duke.edu
First Name & Middle Initial & Last Name & Degree
Charles Gerardo, MD
Facility Name
Texas Tech University Health Sciences Center El Paso
City
El Paso
State/Province
Texas
ZIP/Postal Code
79905
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susan Watts
Phone
915-215-4633
Email
susan.watts@ttuhsc.edu
First Name & Middle Initial & Last Name & Degree
Sarah Watkins, DO
Facility Name
UT Health San Antonio
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Cantu, BS
Email
cantud5@uthsca.edu
First Name & Middle Initial & Last Name & Degree
Shawn Varney, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

We'll reach out to this number within 24 hrs